Post-reactivation humoral immune response with Soberana 01 vaccine in IPK workers, 2022.
Open Access
- 15 September 2025
- journal article
- Published by Clinical Biotec S.L. in Bionatura Journal
- Vol. 2 (3) , 16
Abstract
SARS-CoV-2, the causative agent of COVID-19, was declared a pandemic on March 11, 2020, and due to its high morbidity and mortality rates, it became a global health priority. Cuba developed its vaccines (SOBERANA 01, 02, and Plus), and as part of an intervention study launched in 2021 among healthcare workers, a booster dose was administered in November of that year. This study aimed to evaluate the humoral immune response after the SOBERANA 01 booster in workers at the Pedro Kourí Institute of Tropical Medicine (IPK) and to analyze its association with sociodemographic and clinical-epidemiological variables. A total of 418 whole blood and serum samples were collected one month after the booster, and anti-SARS- CoV-2 antibodies were assessed using a lateral flow immunochromatographic assay and the UMELISA SARS-CoV-2 IgG technique. The rapid assay detected IgG in 95.7% of samples and marginal IgM positivity (0.23%), while UMELISA confirmed IgG in 99.5% of cases. No significant differences were observed according to sociodemographic or clinical characteristics, although a positive association was found between prior COVID-19 infection and rapid test positivity. These findings demonstrate that SOBERANA 01 induces a strong humoral response in healthcare workers, supporting its use in high-risk populations and confirming that Cuban-developed vaccines provide immune protection comparable to internationally recognized platforms.Keywords
This publication has 23 references indexed in Scilit:
- Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWsDiagnostic Microbiology and Infectious Disease, 2022
- An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in TurkeyJournal of Medical Virology, 2022
- Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in IsraelJAMA, 2022
- Do health-care workers need a COVID-19 vaccine booster?The Lancet Infectious Diseases, 2021
- SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3New England Journal of Medicine, 2021
- SARS-CoV-2, COVID-19 and the aging immune systemNature Aging, 2021
- SARS-CoV2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies2021
- Spike-antibody waning after second dose of BNT162b2 or ChAdOx1The Lancet, 2021
- Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variantsbioRxiv, 2021
- The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, ChinaInternational Journal of Infectious Diseases, 2020